See more : Vario Secure Inc. (4494.T) Income Statement Analysis – Financial Results
Complete financial analysis of Ampio Pharmaceuticals, Inc. (AMPE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ampio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Landcadia Holdings III, Inc (LCY) Income Statement Analysis – Financial Results
- Booking Holdings Inc. (0W2Y.L) Income Statement Analysis – Financial Results
- Belvoir Group PLC (BLV.L) Income Statement Analysis – Financial Results
- Estre Ambiental, Inc. (ESTRF) Income Statement Analysis – Financial Results
- Amati AIM VCT plc (AMAT.L) Income Statement Analysis – Financial Results
Ampio Pharmaceuticals, Inc. (AMPE)
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 76.79K | 50.00K | 50.00K | 18.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 250.00K | 2.08M | 1.09M | 1.18M | 1.27M | 523.00K | 568.00K | 950.00K | 369.31K | 2.24M | 1.74M | 1.45M | 0.00 | 0.00 | 0.00 | 950.00 | 0.00 | 0.00 |
| Gross Profit | -250.00K | -2.08M | -1.09M | -1.18M | -1.27M | -523.00K | -568.00K | -950.00K | 793.15K | -2.16M | -1.69M | -1.40M | 18.75K | 0.00 | 0.00 | -950.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 68.23% | -2,818.46% | -3,376.00% | -2,798.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.44M | 8.92M | 11.90M | 9.17M | 12.62M | 6.83M | 10.42M | 10.55M | 18.96M | 26.92M | 18.29M | 7.49M | 6.65M | 1.97M | 1.07M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Other Expenses | 0.00 | 1.94M | 0.00 | 12.00K | 56.00K | 0.00 | 323.55K | 143.80K | 0.00 | 0.00 | 0.00 | 0.00 | 34.01K | 0.00 | 0.00 | 950.00 | 1.20K | 0.00 |
| Operating Expenses | 9.27M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.10M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Cost & Expenses | 9.52M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.46M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Interest Income | 348.00K | 220.00K | 4.00K | 12.00K | 77.00K | 5.00K | 3.09K | 23.48K | 59.85K | 22.26K | 12.29K | 21.94K | 6.68K | 815.00 | 1.09K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.36K | 19.55K | 4.18K | 2.65K | 0.00 | 0.00 |
| Depreciation & Amortization | 127.00K | 2.08M | 1.09M | 1.18M | 1.27M | 1.28M | 1.21M | 1.21M | 1.14M | 439.10K | 137.68K | 62.40K | 42.55K | 815.00 | 0.00 | 0.00 | 2.19K | 0.00 |
| EBITDA | 0.00 | -18.30M | 0.00 | 0.00 | -17.30M | 35.26M | -14.46M | -14.81M | -23.34M | 0.00 | -23.89M | -11.76M | -11.08M | -8.01M | -21.87K | -29.23K | -26.81K | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,760.35% | -50,310.73% | -47,747.81% | -23,472.97% | -59,119.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.52M | -24.21M | -25.16M | -15.22M | -23.45M | -11.18M | -15.56M | -17.08M | -33.30M | -39.07M | -24.02M | -11.82M | -11.13M | -6.70M | -21.87K | -29.23K | -29.00K | -1.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,864.79% | -50,882.57% | -48,047.74% | -23,641.65% | -59,382.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 886.00K | 4.05M | 3.50M | -60.00K | 4.95M | 45.17M | -36.22M | -2.08M | -412.07K | -7.60M | -504.16K | 227.29K | -7.14M | -1.35M | -4.18K | -2.65K | -2.19K | 0.00 |
| Income Before Tax | -8.63M | -16.34M | -17.08M | -15.89M | -13.63M | 33.99M | -51.89M | -19.16M | -33.71M | -39.05M | -24.53M | -11.59M | -18.28M | -8.05M | -26.05K | -31.88K | -31.20K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,900.24% | -50,853.58% | -49,056.85% | -23,186.23% | -97,475.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.87M | -4.59M | 604.00K | -4.95M | 45.17M | 36.33M | 1.04M | -1.29M | -923.52K | -519.87K | -68.00 | 82.50K | 18.73K | 0.00 | 0.00 | 800.00 | 1.00K |
| Net Income | -8.63M | -8.47M | -12.49M | -16.50M | -8.68M | 33.99M | -51.89M | -19.16M | -32.01M | -38.13M | -24.01M | -11.59M | -18.36M | -8.05M | -26.05K | -31.88K | -32.00K | -1.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,753.66% | -49,650.87% | -48,017.12% | -23,186.09% | -97,915.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -10.67 | -11.24 | -18.79 | -28.63 | -18.32 | 92.10 | -239.13 | -107.06 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| EPS Diluted | -10.66 | -11.24 | -18.59 | -27.71 | -18.32 | 91.90 | -238.41 | -106.91 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| Weighted Avg Shares Out | 809.00K | 753.62K | 664.33K | 576.16K | 474.03K | 369.00K | 217.00K | 179.00K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
| Weighted Avg Shares Out (Dil) | 810.11K | 753.62K | 671.49K | 595.41K | 474.03K | 369.81K | 217.66K | 179.24K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
-$0.04 Earnings Per Share Expected for Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) This Quarter
Wall Street brokerages expect Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) to post earnings of ($0.04) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Ampio Pharmaceuticals’ earnings. Ampio Pharmaceuticals reported earnings per share of ($0.03) in...
Regeneron's Latest Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Regeneron's dupixent gets an approval. AbbVie walks out of Assembly Biosciences partnership. Ampio will begin a COVID-19 trial.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Shares Gap Up to $0.57
Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) gapped up prior to trading on Friday . The stock had previously closed at $0.33, but opened at $0.57. Ampio Pharmaceuticals shares last traded at $0.57, with a volume of 3,610,200 shares changing hands. Separately, Zacks...
Health News Roundup: Clover launches sixth Chinese COVID-19 vaccine trial; UK lowers Covid-19 alert level to 'epidemic' from 'exponential' and more
Italy sewage study suggests COVID-19 was there in December 2019 Scientists in Italy have found traces of the new coronavirus in wastewater collected from Milan and Turin in December 2019 - suggesting COVID-19 was already circulating in Northern Italy before...
Large caps deny they're being outgunned by smaller peers in health R&D - Stockhead
The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a drug to market, which more...
Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher
10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December...
Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon
10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic Macular Edema.
Opthea's done it again: Its drug passed its DME clinical trial - Stockhead
Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient phase 2a clinical trial against DME, which is a smaller market than wet-AMD,...
Source: https://incomestatements.info
Category: Stock Reports